Attenuated neuroprotective effect of riboflavin under UV-B irradiation via miR-203/c-Jun signaling pathway in vivo and in vitro
© Tripathi et al.; licensee BioMed Central Ltd. 2014
Received: 17 November 2013
Accepted: 15 April 2014
Published: 7 May 2014
Riboflavin (RF) or vitamin B2 is known to have neuroprotective effects. In the present study, we report the attenuation of the neuroprotective effects of RF under UV-B irradiation. Preconditioning of UV-B irradiated riboflavin (UV-B-RF) showed attenuated neuroprotective effects compared to that of RF in SH-SY5Y neuroblostoma cell line and primary cortical neurons in vitro and a rat model of cerebral ischemia in vivo.
Results indicated that RF pretreatment significantly inhibited cell death and reduced LDH secretion compared to that of the UV-B-RF pretreatment in primary cortical neuron cultures subjected to oxygen glucose deprivation in vitro and cortical brain tissue subjected to ischemic injury in vivo. Further mechanistic studies using cortical neuron cultures revealed that RF treatment induced increased miR-203 expression which in turn inhibited c-Jun expression and increased neuronal cell survival. Functional assays clearly demonstrated that the UV-B-RF preconditioning failed to sustain the increased expression of miR-203 and the decreased levels of c-Jun, mediating the neuroprotective effects of RF. UV-B irradiation attenuated the neuroprotective effects of RF through modulation of the miR-203/c-Jun signaling pathway.
Thus, the ability of UV-B to serve as a modulator of this neuroprotective signaling pathway warrants further studies into its role as a regulator of other cytoprotective/neuroprotective signaling pathways.
KeywordsCerebral ischemia Riboflavin UV-B miR-203 C-jun Neuroprotection
Cerebral stroke, a leading cause of death and disability worldwide involves cerebral ischemia-reperfusion injury and impaired blood flow resulting in neuronal cell death [1, 2]. Despite the recent efforts for improvement of treatment strategies for cerebral stroke, prognosis of cerebral ischemia patients has remained largely unsatisfactory. This is attributed to the lack of effective neuroprotective agents for salvaging neuronal cell death as in most cases only the recombinant tissue plasminogen activator (rtPA) is routinely used for treatment . Therefore, the need for expedited development of effective neuroprotective agents for cerebral stroke is critical.
Understanding of the complex pathophysiology of ischemic stroke is imperative for identifying promising neuroprotective agents and therapeutic strategies . Recent studies have established microRNAs (miRs) as novel regulators of brain function with roles in cerebral ischemia and injury, neuroprotection, and neurodegeneration [3–7].
At current rates, it takes a reasonably long period of time for a lead compound to be developed into a clinically approved drug for cerebral ischemia [2, 3]. An arguably faster path to development is to repository dietary agents or neutraceuticals as neuroprotective agents for improvement of cerebral stroke outcome . The insufficiency of vitamins and antioxidants leads to increased cognitive injury in stroke patients [9, 10]. In particular, riboflavin (vitamin B2) is known to have promising neuroprotective effects [9–12]. However, RF contains a photosensitive isoalloxazine ring making it vulnerable to the atmospherically predominant UV-B radiation (280-315 nm) induced photodegradation, which might compromise its neuroprotective effects [13–15]. In the present study, we examined the neuroprotective effects of RF and UV-B-RF in a rat model of cerebral ischemia and cortical neurons and investigated the molecular mechanisms involved in this process.
The human neuroblastoma SH-SY5Y was obtained from American Type Culture Collection (ATCC, Rockville, MD). Riboflavin, para-formaldehyde, sucrose, poly-l-lysine, 2, 3, 5-triphenyl tetrazolium chloride (TTC), Nembutal, 4′, 6-diamidino-2-phenylindole (DAPI) all are procured from Sigma (St. Louis, MO, USA). The firefly luciferase reporter plasmid (Genecopeia Inc., Rockville, MD, USA) and the miRNA mimic was procured from Ambion (Ambion, Austin, TX, USA). The Lipofectamine 2000 and RNAiMax were from Invitrogen (Invitrogen, Carlsbad, CA,USA). The dual luciferase assay kit was purchased from Promega (Promega, Madison, WI, USA). A 3–0 rounded-tip nylon monofilament suture was procured from Ethicon. The cell counting kit-8 (CCK-8) was from Dojinando Laboratory (Dojindo Molecular Technologies, Inc. Rockville, MD,USA). The RT2miRNA PCR array system was procured from Qiagen (Qiagen, Hilden, Germany). The primary antibodies (p-H2AX (Cat No 9718), Cleaved Casapse-3 (Cat No 9661), c-Jun (Cat No 9165), and Beta Actin (Cat No 4967) were procured from the Cell Signaling Technology (Cell Signaling Technologies, Boston, MA, USA) The secondary antibodies used in the experiments were from Chemicon (Chemicon, Temecula, CA, USA). All other chemicals were purchased from Sigma (St. Louis, MO, USA) unless otherwise stated.
The UV-irradiation system (Vilber Lourmat, France), was equipped with calibrated UV-B detection probe and comprised of an array of 1.2 m long UV-B emitting tubes for regulated emission of radiation through a microprocessor-controlled RMX-3 W radiometer. The spectral emission of UV-B source used for the experiments ranged from 280 to 320 nm with a peak at 315 nm. Intensity of UV-B (0.6 mW/cm2 for 1 h) selected for irradiation was based on dosimetry carried out between 12.00 Noon to 1.00 PM and was parallel to the ambient intensity of UV-B radiation in sunlight at Lucknow (26°45′N latitude and 80°50′E longitude at 146 m above the mean sea level). UV-B irradiation was carried out in a temperature controlled (25°C ± 2°C) radiation chamber. The riboflavin samples in glass Petri dishes (60 × 15 mm) were placed at a minimum distance of 22.0 cm from the source of radiation.
Liquid chromatography-mass spectrometry (LC-MS/MS) analysis
Mass spectrometric detection was performed on an API 4000 QTRAP mass spectrometer (Applied Biosystems, Canada). RF was optimized by continuous infusion at 10 μl min−1 using syringe pump (Model ‘11’, Harvard apparatus). Zero air and nitrogen gas were used as source and curtain gas, respectively. The optimized declustering potential was 120 Volt. At these optimized conditions, Q1 scan for control and test samples was performed.
Cell culture and transfections
SH-SY5Y cells were maintained plated in 100-mm cultured dishes and cultured in Eagle’s modified essential medium/ F12, supplemented with 10% fetal calf serum, 1% of a mixture of penicillin/streptomycin/nystatin, 1 mM sodium piruvate, 0.1 Mm non-essential amino acids,1.5 g/L sodium bicarbonate and 2 mM L-Glutamine. RF was dissolved in saline (0.9% NaCl) and stock solutions (10 mM) were further diluted in the culture media prior to the use in experiments. The cells were plated at 1×104cells per well in 96-well or 5×105cells per well in 6 well microtiter plates for the assays. For the primary cortical neuronal cultures, embryonic day 16–18 pups were obtained from pregnant Sprague Dawley rats, anesthetized with tribromoethanol (350 mg/kg, i.p.). Meninges were carefully removed and isolated cerebral cortices were dissociated with 8.2 U/ml papain (Worthington Biochemical, Lakewood, NJ) for 30 min at 37°C in a shaking water bath. Subsequently, fetal bovine serum and trypsin inhibitor were used to stop digestion. The tissue suspension was then triturated thoroughly using a pasteur pipette. Freshly dissociated cells were seeded at 2 × 105 cells/cm2 into 96-well plastic plates coated with L-polyornithine (10 μg/ml) and then incubated in Neurobasal medium (Invitrogen, Carlsbad, CA) with 2% B-27 supplement, Glutamax (1:100) (Invitrogen, Calsbad, CA), penicillin, and streptomycin at 37°C with 5% CO2 and 95% air. The medium was changed 24 h after plating, and half of the medium was changed every 3 days. Experiments were conducted after three changes of media. Immunocytochemical analysis of neuronal marker protein gene product 9.5 (PGP 9.5) (Chemicon International, Inc., Temecula, CA) was used to confirm the purity of neuronal cells. The transfections were carried out by using either Lipofectamine 2000 or RNAiMax (Invitrogen, Carlsbad,CA,USA) as per a standardized protocol .
Measurement of cell viability and LDH secretion
The cell viability and LDH secretion were quantified in the SH-SY5Y cell line and cortical neuron cultures using the Cell Counting Kit-8 (Dojindo, Molecular Technologies, MD, USA) and the LDH quantification kit (Biovision, CA, USA) as per the manufacturer’s instructions.
Oxygen glucose deprivation
For oxygen glucose deprivation (OGD) experiments, the media of cultured SH-SY5Y cell line or cortical neurons were replaced with pre gassed 1X Hank’s balanced salt solution (HBSS, 140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 10 mM HEPES, 30 μM glycine, pH 7.4) and placed in a Billups-Rothenberg modular incubator chamber (Del Mar, CA) and flushed with a gas mixture of 5% CO2 and 95% N2 for 10 min. The chamber was then sealed and placed into a humidified CO2 incubator at 37°C. After 60 min in the hypoxic chamber, the OGD treatment was stopped by replacing HBSS with the respective cell culture media. The cells were then placed back to normoxic conditions and incubated for 24 h for the functional assays.
Focal cerebral ischemia and neurological deficit score evaluation
Focal cerebral ischemia was simulated in a rat model of cerebral stroke through the middle cerebral artery occlusion (MCAO). Adult male Sprague–Dawley (SD) rats (220 ± 20 g) were obtained from the National Laboratory Animal Centre, Central Drug Research Institute (CDRI), Lucknow, used for experiment. The experimental animals were approved by Institutional Animal Ethical Committee (IAEC) and all animal experiments were carried out in accordance with the institutional guidelines. Rats were housed in cages in a temperature-controlled (25°C ± 1°C) environment, provided free access to food and purified drinking water ad libitum. The rats were divided into 4 groups of 6 rats each as follows: Group I: Sham operated group; handled as other groups, except MCAO was not done. Group II: Ischemic brain damage induced by MCAO, treated with saline as vehicle. Group III: Ischemic brain damage, treated with 10 mg/kg of RF 30 min before MCAO. Group IV: Ischemic brain damage, treated with 10 mg/kg UV-B irradiated RF 30 min before MCAO. The induction of MCAO and evaluation of the neurological deficit score was conducted as per a standardized protocols [17, 18]. At the end of the experimental period the animals were sacrificed through decapitation.
Western blotting experiments were carried out using previously standardized protocol . Briefly both cells and tissues lysates were prepared in cell lysis buffer (50 mMol/L Tris–HCl, 150 mmol/L NaCl, 1% NP40, 0.5% SDS, and 1% deoxycholic acid). The lysates were subsequently heated at 95°C for 5 minutes and centrifuged at 14,000X g for 5 min and the supernatants were stored at −80°C until use. 50 μg of estimated protein per sample was loaded on to 10% SDS-PAGE gels. Blocking was done with 2% BSA and blots were incubated in primary antibodies (1:5000) over night at 4°C. The blots were washed thrice in 0.1% Tween-20 in PBS and incubated with HRP-conjugated secondary antibody (1:2000) for 1 h at room temperature. Blots were developed using the chemiluminescent substrate (Millipore, Billerica, CA, USA).
Total miRNA was isolated from the cortical tissues samples and cortical neuronal cultures using the Nucleospin miRNA kit (Macherey–Nagel, Duren, Germany). The change in miRNA expression was measured using the RT2 miRNA PCR array system (Qiagen, Hilden, Germany). Expression analysis of 376 miRNA sequences was performed as per the manufacturer’s instructions in a Light Cycler 480 II (Roche Diagnostics, Mannheim, Germany). The PCR conditions were set according to the manufacturer’s instructions. Data analysis was performed using the RT2 Profiler PCR Array Data Analysis Template ( Qiagen, Hilden, Germany). Normalization of the data was done using four miRNAs (hsa-SNORD-44, hsa-SNORD47, hsa-SNORD48 and hsa-U6) and the relative miRNA expression levels were calculated with 2-ΔΔCt. All the experiments were performed in triplicate.
Site directed mutagenesis and real-time PCR
The expression vector of c-Jun deletion mutant N1–220 was generated in pcDNA3.1 vector by PCR. The expression vectors of c-Jun mutant (pcDNA3.1junS63/73A and pcDNA3.1junM3A) were generated in pcDNA3.1 vector by PCR using a previously standardized site-directed mutagenesis method . All generated constructs were verified by sequencing.
Real-time PCR analysis
mRNA from the samples was extracted using Trizol. To evaluate the level of c-Jun expression, realtime PCR with SYBR Green dye was used in a LC480 II light cycler real time PCR machine. The real time PCR reaction mixture contained 10 μl Syber Green Super Mix, 100 nM of each primer (c-Jun Forward Primer: 3′- TGATGACGCCTTACGTGGTA-5′ and Reverse Primer:3′- ACAAGGTGTTCCGAGCTGTT-5′) and 1 μl cDNA. All samples were run in triplicates and each experiment was repeated at least three times independently. Each sample was normalized on the basis of GAPDH.
The luciferase reporter plasmids containing the wild-type 3′UTR with the miR-203 binding site of c-Jun was obtained from Genecopoeia (Rockville, MD, USA). respectively. Cortical neuron cells were transfected with the luciferase constructs (100 ng per 24-well) and pre-miR-203 or pre-miR-Control (10 nM, Applied Biosystems) using Lipofectamin 2000 (Invitrogen). Luciferase activity was measured after 24 h using the Dual Luciferase Reporter Assay according to the manufacturer’s instructions (Promega, Madison, WI, USA).
All the values are represented as mean ± SEM from at least three independent experiments. Data was analysed using One-way ANOVA followed by Newman Keuls multiple comparision test. Values with p < and =0.05 were considered to be significant.
UV-B irradiation induces degradation of RF and decreases its neuroprotective effects in vitro
UV-B-RF has attenuated neuroprotective effects in a rat model of cerebral ischemia
UV-B irradiation differentially regulates RF induced expression of miR-203 in-vivo and in-vitro
Effect of RF and UV-B-RF treatment on differential expression of miRNAs cerebral cortex in vivo and cortical neuronal culture in vitro
Expression of miRNAs in rat cerebral cortex treated RF and UV-B-RF
RF Pre- treatment (Fold Change)
UV-B irradiated RF-pre treatment (Fold Change)
Expression of miRNAs in rat primary cortical neurons treated with RF and UV-B-RF
UV-B irradiation alters the neuroprotective ability of RF through modulation of the miR-203/c-Jun signaling pathway
Discussion and conclusion
Riboflavin is a water-soluble, heat stable and light sensitive vitamin existing in a wide variety of foods [8, 12]. Riboflavin has been reported to have neuroprotective effects through reduction of ischemic brain injury in focal cerebral ischemia [10, 12]. The recent interest on the relationship of riboflavin and stroke is focused on the riboflavin deficiency in cerebral stroke patients  and the riboflavin regulation of circulating homocysteine concentrations, a risk factor for cardiovascular disease [8, 12]. However, due to its light sensitive nature we hypothesized that the atmospherically predominant UV-B irradiation may alter the functional properties of RF and other phytochemicals such as piperine and curcumin  influencing its neuroprotective effects. Our study showed that UV-B irradiation significantly alters the neuroprotective effects of RF.
The miR-203 has neuroprotective effects  and it is known to regulate cell proliferation, differentiation and death [21, 22]. Consistent with this finding, our study showed that the RF treatment in neuronal cells induced significantly increased expression of miR-203, decreased OGD induced LDH secretion and increased cell survival compared to that of the UV-B-RF treatment. We further identified c-Jun as a target of miR-203 and its inhibitory effect on c-Jun expression in agreement with earlier studies [21, 22]. This may represent a critical step in the regulation of the neuroprotective effects of RF. The relative decrease in the miR-203 expression with respect to the controls in the cultured neuronal cells or brain tissues treated by UV-B-RF was 0.25 and 050 folds respectively. This finding may possibly due to the existence of a regulatory circuit, in which miR-203 and c-Jun mutually inhibit each other. This may represent a critical step in the neuroprotective action of RF. As c-Jun is a negative regulator of miR-203, the circuit constitutes a feedback loop, whereby RF treatment in neuronal cells had increased levels of miR-203 expression, inducing an inhibition of c-Jun resulting in neuroprotection [23, 24], where as UV-B irradiated RF was devoid of this effect. Thus, our results suggest a novel notion: RF preconditioned neuronal cells have increased while UV-B-RF preconditioned neuronal cells have no marginal change in miR-203 expression thereby leading to differential effects on c-Jun inhibition and neuroprotection. Interestingly, we found RF treatment both in vivo and in vitro significantly increased miR-203 expression and subsequent c-Jun inhibition leading to neuroprotection. Further studies will be needed to understand whether this signaling pathway is a target of other neuroprotective or neurotoxic agents.
Taken together our studies suggest that (i) UV-B irradiation induces attenuation of the neuroprotective effects of RF (ii) through the modulation of the miR-203/c-Jun signaling pathway. Our current results strongly suggest that the potential of UV-B irradiation may be further investigated for its potential as a regulator of other cytoprotective/neuroprotective signaling pathways. Importantly, further studies are required to assess the translational value of the therapeutic activation of the miR-203/c-Jun signaling pathway for neuroprotection.
This study was supported by grants from the Council of Scientific and Industrial Research Network Project-UNDO and the Indian Council of Medical Research (ICMR), New Delhi. Authors thank the members of the DP Mishra laboratory for helpful discussions. The CSIR-CDRI manuscript No is 111/2014/DPM.
- Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischemic stroke: an integrated view. Trends Neurosci. 1999, 22: 391-397. 10.1016/S0166-2236(99)01401-0.View ArticlePubMedGoogle Scholar
- Minnerup J, Sutherland BA, Buchan AM, Kleinschnitz C: Neuroprotection for Stroke: Current Status and Future Perspectives. Int J Mol Sci. 2012, 13: 11753-11772. 10.3390/ijms130911753.PubMed CentralView ArticlePubMedGoogle Scholar
- Saugstad JA: MicroRNAs as effectors of brain function with roles in ischemia and injury, neuroprotection and neurodegeneration. J Cereb Blood Flow Metab. 2010, 30: 1564-1576. 10.1038/jcbfm.2010.101.PubMed CentralView ArticlePubMedGoogle Scholar
- Kocerha J, Kauppinen S: Wahlestedt C: microRNAs in CNS disorders. Neuromolecular Med. 2009, 11: 162-172. 10.1007/s12017-009-8066-1.View ArticlePubMedGoogle Scholar
- Dharap A, Bowen K, Place R, Li LC, Vemuganti R: Transient focal ischemia induces extensive temporal changes in rat cerebral microRNAome. J Cereb Blood Flow Metab. 2009, 29: 675-687. 10.1038/jcbfm.2008.157.PubMed CentralView ArticlePubMedGoogle Scholar
- Jeyaseelan K, Lim KY, Armugam A: MicroRNA expression in the blood and brain of rats subjected to transient focal ischemia by middle cerebral artery occlusion. Stroke. 2008, 39: 959-966. 10.1161/STROKEAHA.107.500736.View ArticlePubMedGoogle Scholar
- Liu DZ, Tian Y, Ander BP, Xu H, Stamova BS, Zhan X, Turner RJ, Jickling G, Sharp FR: Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab. 2010, 30: 92-101. 10.1038/jcbfm.2009.186.PubMed CentralView ArticlePubMedGoogle Scholar
- Powers HJ: Current knowledge concerning optimum nutritional status of riboflavin, niacin and pyridoxine. Proc Nutr Soc. 1999, 58: 435-440. 10.1017/S0029665199000579.View ArticlePubMedGoogle Scholar
- Gariballa S, Ullegaddi R: Riboflavin status in acute ischaemic stroke. Eur J Clin Nutr. 2007, 61: 1237-1240. 10.1038/sj.ejcn.1602666.View ArticlePubMedGoogle Scholar
- Betz AL, Ren XD, Ennis SR, Hultquist DE: Riboflavin reduces edema in focal cerebral ischemia. Acta Neurochir Suppl (Wien). 1994, 60: 314-317.Google Scholar
- Hoane MR, Wolyniak JG, Akstulewicz SL: Administration of riboflavin improves behavioral outcome and reduces edema formation and Glial Fibrillary Acid Protein expression following traumatic brain injury. J Neurotrauma. 2005, 22: 1112-1122. 10.1089/neu.2005.22.1112.View ArticlePubMedGoogle Scholar
- Zou YX, Zhang XH, Su FY, Liu X: Importance of riboflavin kinase in the pathogenesis of stroke. CNS Neurosci Ther. 2012, 18: 834-840. 10.1111/j.1755-5949.2012.00379.x.View ArticlePubMedGoogle Scholar
- Joshi PC: Comparison of the DNA-damaging property of photosensitised riboflavin via singlet oxygen (1O2) and superoxide radical O2-. Mechanisms. Toxicol Lett. 1985, 26: 211-217. 10.1016/0378-4274(85)90169-9.View ArticlePubMedGoogle Scholar
- Joshi PC: Ultraviolet radiation-induced photodegradation and 1O2, O2-. production by riboflavin, lumichrome and lumiflavin. Indian J Biochem Biophys. 1989, 26: 186-189.PubMedGoogle Scholar
- Joshi PC, Gray TA, Keane TC: Protection of riboflavin and UVB sensitized degradation of DNA and RNA bases by natural antioxidants. Ecotoxicol Environ Saf. 2012, 78: 86-90.View ArticlePubMedGoogle Scholar
- Rastogi N, Gara RK, Trivedi R, Singh A, Dixit P, Maurya R, Duggal S, Bhatt ML, Singh S, Mishra DP: Gingerol induced myeloid leukemia cell death is initiated by reactive oxygen species and activation of miR-27b expression. Free Radic Biol Med. 2014, 68 (6): 288-301.View ArticlePubMedGoogle Scholar
- Rathore P, Dohare P, Varma S, Ray A, Sharma U, Jagannathan NR, Ray M: Curcuma oil: reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain. Neurochem Res. 2008, 33: 1672-1682. 10.1007/s11064-007-9515-6.View ArticlePubMedGoogle Scholar
- Tripathi AK, Shakir A, Mishra DP: Attenuated Antioxidant property of UV-B Irradiated piperine in Ischemia-Reperfusion Injury in SD rat. G- J of Env Sci and Technol. 2013, 1: 29-36.Google Scholar
- Higuchi R, Krummel B, Saiki RK: A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucleic Acids Res. 1988, 16: 7351-7367. 10.1093/nar/16.15.7351.PubMed CentralView ArticlePubMedGoogle Scholar
- Cao L, Feng C, Li L, Zuo Z: Contribution of microRNA-203 to the isoflurane preconditioning induced Neuroprotection. Brain Res Bull. 2012, 88: 525-528. 10.1016/j.brainresbull.2012.05.009.PubMed CentralView ArticlePubMedGoogle Scholar
- Sonkoly E, Wei T, Pavez Lorie E, Suzuki H, Kato M, Torma H, Ståhle M, Pivarcsi A: Protein kinase C dependent upregulation of miR-203 induces the differentiation of human keratinocytes. J Invest Dermatol. 2009, 130: 124-134.View ArticleGoogle Scholar
- Sonkoly E, Lovén J, Xu N, Meisgen F, Wei T, Brodin P, Jaks V, Kasper M, Shimokawa T, Harada M, Heilborn J, Hedblad MA, Hippe A, Grandér D, Homey B, Zaphiropoulos PG, Arsenian-Henriksson M, Ståhle M, Pivarcsi A: MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma. Onco Genesis. 2012, 12: 1:e3-doi: 10.1038/oncsis.2012.3Google Scholar
- Braithwaite SP, Schmid RS, He DN, Sung ML, Cho S, Resnick L, Monaghan MM, Hirst WD, Essrich C, Reinhart PH, Lo DC: Inhibition of c-Jun Kinase Provides Neuroprotection in a Model of Alzheimer’s Disease. Neurobiol Dis. 2010, 39: 311-317. 10.1016/j.nbd.2010.04.015.PubMed CentralView ArticlePubMedGoogle Scholar
- Wisdom R, Johnson RS, Moore C: c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 1999, 18 (1): 188-197. 10.1093/emboj/18.1.188.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.